Virvio is a pre-clinical biotherapeutic discovery company and world leader in computationally designed protein scaffolds called "mini-binders"​. Our platform generates mini-binder leads having antibody-like affinity and specificity yet also possessing the hyper-stability and manufacturability of small-molecule drugs. Mini-binders are small structured proteins designed completely de novo to meet the requirements of the molecular target and indication.